Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial

Affiliations

• ¹ Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
• ² Imperial College, London, UK.
• ³ Université de Lorraine, Inserm INI-CRCT, CHRU, Nancy, France.
• ⁴ Department of Medicine, University of Mississippi School of Medicine, Jackson, MS, USA.
• ⁵ National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece.
• ⁶ Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.
• ⁷ Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
• ⁸ Boehringer Ingelheim International, Ingelheim, Germany.
• ⁹ Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.
• ¹⁰ Biostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
• ¹¹ Department of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.